Methods and compositions for predicting and treating uveal melanoma

Here, in multi-scale analyses using single-cell RNA sequencing of six different primary uveal melanomas, inventors uncover a previously unrecognized intratumor heterogeneity at the genetic and transcriptomic level. They identify distinct transcriptional cell states and diverse tumor-associated populations in a subset of primary uveal melanomas.

Keywords: RNA signature, Prognosis, Uveal Melanoma, Intratumor heterogeneity
Patent Application number: European Procedure (Patents) (EPA) - 16 Nov. 2020 - 20 306 384.7
Inventors:
BERTOLOTTO CorineBALLOTTI RobertSTRUB ThomasPANDIANI Charlotte
Publications:
Cell Death Differ. 2021 Jun 28 Pandiani et al Single-cell RNA sequencing reveals intratumoral heterogeneity in primary uveal melanomas and identifies HES6 as a driver of the metastatic disease. DOI: 10.1038/s41418-020-00730-7Prog Retin Eye Res 2021 Apr 13 Strub et al Translation of single-cell transcriptomic analysis of uveal melanomas to clinical oncology DOI: 10.1016/j.preteyeres.2021.100968

Reference:

BIO20429-D1

    Business Developper
    contact
    Inserm Transfert
    Business Developer
    Patent filling date: 16-11-2020
    Rare disease: No
    Second indication: No

    You might also be interested in